GLSI is a clinical-stage company focused on GP2, an immunotherapy candidate aimed at preventing breast cancer recurrence after surgery. With no approved products yet, these reports matter mainly for insights into clinical progress, spending patterns, and how long the cash will last. The Flamingo-01 Phase 3 trial is the main value driver, so its cost trajectory directly affects the runway. The wider loss per share and higher R&D outlay this quarter give a clear signal on trial execution and funding sustainability through what could be a long regulatory process.
For the third quarter ended September 30, 2026, GLSI posted a net loss of $5.81 million versus $3.71 million in the same quarter last year. Basic and diluted loss per share came in at $0.40, compared with $0.27 previously. Over the first nine months, the net loss reached $15.42 million, up from $10.2 million, with loss per share at $1.05 versus $0.76. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The $0.40 loss per share missed the roughly $0.34 consensus estimate. Revenue remained zero, as expected for this pre-revenue profile. The bigger loss stemmed mainly from the 67% year-over-year jump in R&D tied to Flamingo-01, plus a cash position of about $5.9 million that prompted the going-concern note and ongoing ATM use.
Sentiment was already measured heading into the release because of the rising burn rate and tight balance sheet. The wider loss and going-concern disclosure added to worries about near-term dilution via the ATM. Without revenue to support valuation, the share price reacts more to financing updates and trial milestones than to standard earnings beats. Discussion after the report has focused on whether faster Flamingo-01 enrollment offsets the higher spend and how future raises might affect existing holders.
The key item remains execution on the Flamingo-01 Phase 3 trial. As enrollment grows, R&D will likely keep driving expenses, so investors will want to see whether trial momentum points to clearer data timelines.
Cash runway comes next. With roughly $5.9 million on hand and a nine-month operating burn near $9.6 million, continued ATM access or other financing looks probable. Dilution effects, raise terms, and management comments on capital will influence sentiment.
Finally, monitor GP2 updates on clinical progress, regulatory steps, and any partnership talks that could ease funding pressure. For a pre-revenue biotech, catalysts and financing decisions outweigh quarterly profits in the periods ahead. I’m watching this closely as trial data and capital moves unfold.
When reviewing clinical-stage names like GLSI, I often turn to Tickeron’s AI Screener to quickly compare peers and spot technical patterns. It streamlines scanning for similar opportunities and helps keep track of sector shifts without hours of manual work. This kind of resource has become a regular part of how I evaluate biotech setups and stay informed on comparable names.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.
GLSI broke above its upper Bollinger Band on November 18, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 40 similar instances where the stock broke above the upper band. In 35 of the 40 cases the stock fell afterwards. This puts the odds of success at 88%.
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
The 10-day moving average for GLSI crossed bearishly below the 50-day moving average on November 11, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 15 of 20 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 75%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GLSI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
The Aroon Indicator for GLSI entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Momentum Indicator moved above the 0 level on November 17, 2026. You may want to consider a long position or call options on GLSI as a result. In 77 of 91 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 85%.
The Moving Average Convergence Divergence (MACD) for GLSI just turned positive on November 17, 2026. Looking at past instances where GLSI's MACD turned positive, the stock continued to rise in 42 of 45 cases over the following month. The odds of a continued upward trend are 90%.
GLSI moved above its 50-day moving average on November 17, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +49.56% 3-day Advance, the price is estimated to grow further. Considering data from situations where GLSI advanced for three days, in 213 of 266 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. GLSI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 58 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 94 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: GLSI's P/B Ratio (71.438) is slightly higher than the industry average of (3.596). P/E Ratio (-9.541) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (443.347).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GLSI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry Biotechnology